“…Therapeutic options that are available for the treatment of infections caused by Fusarium sp. include: (1) single antifungal agents including: amphotericin-B, voriconazole, posaconazole and itraconazole; (2) combination therapies including either two antifungal agents such as voriconazole + amphotericin-B, voriconazole + terbina ine, caspofungin + amphotericn-B or amphotericin-B + terbina ine; or one antifungal drug + one non-antimycotic agent such as: voriconazole + metronidazole, and liposomal amphotericin-B + cipro loxacin or ibuprofen; (3) adjunctive therapies such as: surgical debridement of infected tissues, debulking surgery such as splenectomy, removal of infected or colonized CVCs, interferon-γ, G-CSF, and granulocyte transfusions; and (4) new agents such as: MGCD290 and isavaconazole [2,4,[6][7][8][9][10][11]14,[18][19][20][34][35][36]. In severely immunocompromised patients who are at high-risk of having DFIs, antifungal prophylaxis is indicated [14,15].…”